Innoviva Inc
$ 20.86
-0.57%
03 Dec - close price
- Market Cap 1,659,873,000 USD
- Current Price $ 20.86
- High / Low $ 21.23 / 20.84
- Stock P/E 13.37
- Book Value 13.51
- EPS 1.66
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.15 %
- 52 Week High 22.76
- 52 Week Low 16.52
About
Innoviva, Inc. is a biopharmaceutical company based in Burlingame, California, focused on the development and commercialization of innovative therapies for respiratory diseases. Through proprietary technologies and strategic collaborations, Innoviva aims to deliver advanced treatment solutions that enhance patient outcomes. The company maintains a diverse pipeline addressing significant unmet medical needs in respiratory healthcare, reflecting its commitment to improving patient quality of life and advancing the industry's standards of care.
Analyst Target Price
$36.40
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-02-29 | 2023-11-01 | 2023-08-02 | 2023-05-09 | 2023-02-28 |
| Reported EPS | 0.3846 | 0.77 | -0.7429 | 0.26 | 0.12 | -0.55 | 0.46 | 0.76 | 0.98 | 0.02 | 0.42 | -0.98 |
| Estimated EPS | 0.4 | 0.5 | 0.33 | 0.41 | 0.27 | 0.24 | 0.17 | 0.23 | 0.27 | 0.26 | 0.23 | 0.23 |
| Surprise | -0.0154 | 0.27 | -1.0729 | -0.15 | -0.15 | -0.79 | 0.29 | 0.53 | 0.71 | -0.24 | 0.19 | -1.21 |
| Surprise Percentage | -3.85% | 54% | -325.1212% | -36.5854% | -55.5556% | -329.1667% | 170.5882% | 230.4348% | 262.963% | -92.3077% | 82.6087% | -526.087% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None |
| Amount | $0.25 | $0.25 | $0.25 | $0.25 | $0.25 | $5.571428571 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INVA
2025-11-03 04:41:53
The Salford Lung Study showed that Relvar Ellipta significantly improved asthma control in patients compared to their usual care. Patients initiated on Relvar Ellipta had twice the odds of achieving an improvement in asthma control, as measured by the Asthma Control Test (ACT). This real-world study highlights the effectiveness of Relvar Ellipta in everyday clinical practice for asthma management.
2025-11-02 10:49:58
Innoviva, Inc. reported strong financial results for Q4 and full-year 2024, with its core royalty platform and specialty therapeutics business achieving significant year-over-year revenue growth. Key highlights include GSK royalties of $255.6 million for the full year and Innoviva Specialty Therapeutics' U.S. net product sales reaching $80.9 million, driven by successful product launches and strategic acquisitions like ZEVTERA®. The company anticipates continued growth in 2025, with forecasted U.S. net product sales exceeding $100 million and key pipeline advancements.
2025-11-02 10:49:58
Innoviva reported strong financial results for Q1 2025, driven by robust cash flows from GSK royalties and significant growth in Innoviva Specialty Therapeutics (IST) product sales. The company highlighted ongoing momentum in its therapeutics platform, including regulatory submissions for zoliflodacin and the anticipated U.S. launch of ZEVTERA® by mid-2025. Innoviva remains focused on creating shareholder value through strategic healthcare investments and disciplined capital allocation.
2025-10-22 00:00:00
Denali Advisors LLC has reduced its stake in Innoviva, Inc. by 11.7% during the second quarter, now holding 332,661 shares valued at approximately $6.68 million. Despite this, other institutional investors have increased their holdings, and Innoviva's stock price saw a 1.1% increase. Recent analyst reports remain favorable, with Oppenheimer initiating coverage with an "outperform" rating and a target price of $45.00.
2025-10-19 00:00:02
This article provides an AI-driven analysis of Innoviva Inc. (NASDAQ: INVA), highlighting weak near and mid-term sentiment, along with a neutral long-term outlook. It details specific institutional trading strategies, including long, breakout, and short positions, tailored to different risk profiles. The analysis also features multi-timeframe signal data and emphasizes elevated downside risk.
2025-10-14 14:47:14
The Investing.com India article reports that Innoviva stock reached a 52-week low, trading at 16.66 USD. The content provided is minimal due to an application error, preventing further details regarding this event.
